MGNX
HealthcareMacroGenics, Inc.
$1.72
+$0.11 (+6.83%)
Jan 5, 2026
Price History (1Y)
Analysis
MacroGenics, Inc. is a biotechnology company within the healthcare sector, with a market capitalization of $108.80M and approximately 341 employees. The company operates in the broader industry of biotechnology. Financially, MacroGenics has reported significant losses, including a net income (TTM) of -$75,886,000 and an EBITDA of -$106,061,000. The company's gross margin is -43.8%, operating margin is 25.6%, and profit margin is -59.5%. In terms of returns, MacroGenics has recorded a return on equity (ROE) of -81.1% and a return on assets (ROA) of -26.5%. The company's balance sheet shows $146.40M in cash and $37.01M in debt, resulting in a debt to equity ratio of 55.24. MacroGenics' valuation metrics include a forward P/E ratio of -1.00 and an EV/EBITDA of 0.07. The company's revenue (TTM) is $127.63M, with a year-over-year revenue growth rate of -34.2% and earnings growth rate of -70.4%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About MacroGenics, Inc.
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Visit website →Key Statistics
- Market Cap
- $108.80M
- P/E Ratio
- N/A
- 52-Week High
- $3.55
- 52-Week Low
- $0.99
- Avg Volume
- 1.29M
- Beta
- 1.52
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 341